Search

Your search keyword '"Daver, Naval"' showing total 4,196 results
Start Over Author "Daver, Naval"
4,196 results on '"Daver, Naval"'

1. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

Author

Bouligny, Ian M., Montalban-Bravo, Guillermo, Sasaki, Koji, Daver, Naval, Jabbour, Elias, Alvarado, Yesid, DiNardo, Courtney D., Ravandi, Farhad, Borthakur, Gautam, Pemmaraju, Naveen, Kadia, Tapan, Masarova, Lucia, Takahashi, Koichi, Andreeff, Michael, Bazinet, Alexandre, Yang, Hui, Kanagal, Rashmi, Pierce, Sherry, Meyer, Meghan, Huang, Xuelin, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

2. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Author

DiNardo, Courtney D., Verma, Divij, Baran, Natalia, Bhagat, Tushar D., Skwarska, Anna, Lodi, Alessia, Saxena, Kapil, Cai, Tianyu, Su, Xiaoping, Guerra, Veronica A., Poigaialwar, Gowri, Kuruvilla, Vinitha M., Konoplev, Sergej, Gordon-Mitchell, Shanisha, Pradhan, Kith, Aluri, Srinivas, Hackman, G. Lavender, Chaudhry, Sovira, Collins, Meghan, Sweeney, Shannon R., Busquets, Jonathan, Rathore, Atul Singh, Deng, Qing, Green, Michael R., Grant, Steven, Demo, Susan, Choudhary, Gaurav S., Sahu, Srabani, Agarwal, Beamon, Spodek, Mason, Thiruthuvanathan, Victor, Will, Britta, Steidl, Ulrich, Tippett, George D., Burger, Jan, Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Kadia, Tapan, Kornblau, Steven, Daver, Naval G., Naqvi, Kiran, Short, Nicholas J., Garcia-Manero, Guillermo, Tiziani, Stefano, Verma, Amit, and Konopleva, Marina

Published
2024
Full Text
View/download PDF

3. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community

Author

Cuglievan, Branko, Kantarjian, Hagop, Rubnitz, Jeffrey E., Cooper, Todd M., Zwaan, C. Michel, Pollard, Jessica A., DiNardo, Courtney D., Kadia, Tapan M., Guest, Erin, Short, Nicholas J., McCall, David, Daver, Naval, Nunez, Cesar, Haddad, Fadi G., Garcia, Miriam, Bhalla, Kapil N., Maiti, Abhishek, Catueno, Samanta, Fiskus, Warren, Carter, Bing Z., Gibson, Amber, Roth, Michael, Khazal, Sajad, Tewari, Priti, Abbas, Hussein A., Bourgeois, Wallace, Andreeff, Michael, Shukla, Neerav N., Truong, Danh D., Connors, Jeremy, Ludwig, Joseph A., Stutterheim, Janine, Salzer, Elisabeth, Juul-Dam, Kristian L., Sasaki, Koji, Mahadeo, Kris M., Tasian, Sarah K., Borthakur, Gautam, Dickson, Samantha, Jain, Nitin, Jabbour, Elias, Meshinchi, Soheil, Garcia-Manero, Guillermo, Ravandi, Farhad, Stein, Eytan M., Kolb, E. Anders, and Issa, Ghayas C.

Published
2024
Full Text
View/download PDF

4. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.

Author

Yacoub, Abdulraheem, Borate, Uma, Rampal, Raajit, Ali, Haris, Wang, Eunice, Gerds, Aaron, Hobbs, Gabriela, Kremyanskaya, Marina, Winton, Elliott, OConnell, Casey, Goel, Swati, Oh, Stephen, Schiller, Gary, McCloskey, James, Palmer, Jeanne, Holmes, Houston, Hager, Steven, Assad, Albert, Erickson-Viitanen, Susan, Zhou, Feng, and Daver, Naval

Subjects
Humans, Primary Myelofibrosis, Phosphatidylinositol 3-Kinases, Pyrazoles, Nitriles, Pyrimidines, Pyrrolidines
Abstract

Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3Kδ inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, and once weekly thereafter (daily-to-weekly dosing; n = 32); or parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing; n = 42). Proportion of patients achieving a ≥10% decrease in spleen volume at 12 weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving ≥50% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.

Published
2024

5. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Author

Daver, Naval, Vyas, Paresh, Kambhampati, Suman, Al Malki, Monzr, Larson, Richard, Asch, Adam, Mannis, Gabriel, Chai-Ho, Wanxing, Tanaka, Tiffany, Bradley, Terrence, Wang, Eunice, Sweet, Kendra, Kantarjian, Hagop, Garcia-Manero, Guillermo, Komrokji, Rami, Xing, Guan, Ramsingh, Giridharan, Renard, Camille, Zeidner, Joshua, Sallman, David, and Jeyakumar, Deepa

Subjects
Humans, Azacitidine, Antibodies, Monoclonal, Humanized, Remission Induction, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols
Abstract

PURPOSE: Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab. We report final phase Ib data for magrolimab with azacitidine in patients with untreated AML ineligible for intensive chemotherapy (ClinicalTrials.gov identifier: NCT03248479). PATIENTS AND METHODS: Patients with previously untreated AML, including TP53-mutant AML, received magrolimab intravenously as an initial dose (1 mg/kg, days 1 and 4), followed by 15 mg/kg once on day 8 and 30 mg/kg once weekly or every 2 weeks as maintenance. Azacitidine 75 mg/m2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and proportion with complete remission (CR). RESULTS: Eighty-seven patients were enrolled and treated; 72 (82.8%) had TP53 mutations with a median variant allele frequency of 61% (range, 9.8-98.7). Fifty-seven (79.2%) of TP53-mutant patients had European LeukemiaNet 2017 adverse-risk cytogenetics. Patients received a median of 4 (range, 1-39) cycles of treatment. The most common treatment-emergent adverse events included constipation (49.4%), nausea (49.4%), and diarrhea (48.3%). Thirty (34.5%) experienced anemia, and the median hemoglobin change from baseline to first postdose assessment was -0.9 g/dL (range, -3.6 to 2.5 g/dL). Twenty-eight (32.2%) patients achieved CR, including 23 (31.9%) patients with TP53 mutations. The median overall survival in TP53-mutant and wild-type patients were 9.8 months and 18.9 months, respectively. CONCLUSION: Magrolimab with azacitidine was relatively well tolerated with promising efficacy in patients with AML ineligible for intensive induction chemotherapy, including those with TP53 mutations, warranting further evaluation of magrolimab with azacitidine in AML. The phase III randomized ENHANCE-2 (ClinicalTrials.gov identifier: NCT04778397) and ENHANCE-3 (ClinicalTrials.gov identifier: NCT05079230) studies are recruiting frontline patients with AML.

Published
2023

7. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis

Author

Urrutia, Samuel, Kantarjian, Hagop M., Ravandi-Kashani, Farhad, Bueso-Ramos, Carlos, Kanagal-Shamanna, Rashmi, Jabbour, Elias, Montalban-Bravo, Guillermo, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Dinardo, Courtney D., Kadia, Tapan M., Masarova, Lucia, Bose, Prithviraj, Pemmaraju, Naveen, Garcia-Manero, Guillermo, and Sasaki, Koji

Published
2024
Full Text
View/download PDF

9. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

Author

Wang, Bofei, Reville, Patrick K., Yassouf, Mhd Yousuf, Jelloul, Fatima Z., Ly, Christopher, Desai, Poonam N., Wang, Zhe, Borges, Pamella, Veletic, Ivo, Dasdemir, Enes, Burks, Jared K., Tang, Guilin, Guo, Shengnan, Garza, Araceli Isabella, Nasnas, Cedric, Vaughn, Nicole R., Baran, Natalia, Deng, Qing, Matthews, Jairo, Gunaratne, Preethi H., Antunes, Dinler A., Ekmekcioglu, Suhendan, Sasaki, Koji, Garcia, Miriam B., Cuglievan, Branko, Hao, Dapeng, Daver, Naval, Green, Michael R., Konopleva, Marina, Futreal, Andrew, Post, Sean M., and Abbas, Hussein A.

Published
2024
Full Text
View/download PDF

10. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia

Author

Montalban-Bravo, Guillermo, Rodriguez-Sevilla, Juan Jose, Swanson, David Michael, Kanagal-Shamanna, Rashmi, Hammond, Danielle, Chien, Kelly, Sasaki, Koji, Jabbour, Elias, DiNardo, Courtney, Takahashi, Koichi, Short, Nicholas, Issa, Ghayas C., Pemmaraju, Naveen, Kadia, Tapan, Ravandi, Farhad, Daver, Naval, Borthakur, Gautam, Loghavi, Sanam, Pierce, Sherry, Bueso-Ramos, Carlos, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

12. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Author

Sallman, David, Al Malki, Monzr, Asch, Adam, Wang, Eunice, Jurcic, Joseph, Bradley, Terrence, Flinn, Ian, Pollyea, Daniel, Kambhampati, Suman, Tanaka, Tiffany, Zeidner, Joshua, Garcia-Manero, Guillermo, Jeyakumar, Deepa, Komrokji, Rami, Lancet, Jeffrey, Kantarjian, Hagop, Gu, Lin, Zhang, Yajia, Tan, Anderson, Chao, Mark, OHear, Carol, Ramsingh, Giridharan, Lal, Indu, Vyas, Paresh, and Daver, Naval

Subjects
Humans, Azacitidine, Myelodysplastic Syndromes, Antibodies, Monoclonal, Humanized, Progression-Free Survival, Leukemia, Myeloid, Acute, Treatment Outcome
Abstract

PURPOSE: Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a dont-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is synergistic with azacitidine, which increases expression of eat-me signals. We report final phase Ib data in patients with untreated higher-risk myelodysplastic syndromes (MDS) treated with magrolimab and azacitidine (ClinicalTrials.gov identifier: NCT03248479). PATIENTS AND METHODS: Patients with previously untreated Revised International Prognostic Scoring System intermediate-/high-/very high-risk MDS received magrolimab intravenously as a priming dose (1 mg/kg) followed by ramp-up to a 30 mg/kg once-weekly or once-every-2-week maintenance dose. Azacitidine 75 mg/m2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and complete remission (CR) rate. RESULTS: Ninety-five patients were treated. Revised International Prognostic Scoring System risk was intermediate/high/very high in 27%, 52%, and 21%, respectively. Fifty-nine (62%) had poor-risk cytogenetics and 25 (26%) had TP53 mutation. The most common treatment-emergent adverse effects included constipation (68%), thrombocytopenia (55%), and anemia (52%). Median hemoglobin change from baseline to first postdose assessment was -0.7 g/dL (range, -3.1 to +2.4). CR rate and overall response rate were 33% and 75%, respectively. Median time to response, duration of CR, duration of overall response, and progression-free survival were 1.9, 11.1, 9.8, and 11.6 months, respectively. Median overall survival (OS) was not reached with 17.1-month follow-up. In TP53-mutant patients, 40% achieved CR with median OS of 16.3 months. Thirty-four patients (36%) had allogeneic stem-cell transplant with 77% 2-year OS. CONCLUSION: Magrolimab + azacitidine was well tolerated with promising efficacy in patients with untreated higher-risk MDS, including those with TP53 mutations. A phase III trial of magrolimab/placebo + azacitidine is ongoing (ClinicalTrials.gov identifier: NCT04313881 [ENHANCE]).

Published
2023

14. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Author

Daver, Naval, Perl, Alexander E, Maly, Joseph, Levis, Mark, Ritchie, Ellen, Litzow, Mark, McCloskey, James, Smith, Catherine C, Schiller, Gary, Bradley, Terrence, Tiu, Ramon V, Naqvi, Kiran, Dail, Monique, Brackman, Deanna, Siddani, Satya, Wang, Jing, Chyla, Brenda, Lee, Paul, and Altman, Jessica K

Subjects
Humans, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Hematology, Rare Diseases, Pediatric, Childhood Leukemia, Cancer, Pediatric Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3mut AML.MethodsThis phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients with FLT3 wild-type and FLT3mut (escalation) or FLT3mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III-defined response criteria.ResultsSixty-one patients were enrolled (n = 56 FLT3mut); 64% (n = 36 of 56) of FLT3mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n = 49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (< 10-2) was achieved in 60% of evaluable mCRc patients (n = 15 of 25). The median overall survival for FLT3mut patients was 10.0 months.ConclusionThe combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure. Dose interruptions were needed to mitigate myelosuppression.

Published
2022

15. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia

Author

Yeh, Jason, Pasvolsky, Oren, Saliba, Rima M., Figgins, Bradley, Wang, Christopher, Fang, Zhou, Ahmed, Sairah, Yilmaz, Musa, Daver, Naval, Ravandi, Farhad, DiNardo, Courtney, Short, Nicholas J., Kadia, Tapan, Al-Atrash, Gheath, Daher, May, Costa, David Marin, Popat, Uday, Champlin, Richard, Shpall, Elizabeth, and Oran, Betül

Published
2024
Full Text
View/download PDF

16. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies

Author

Cuglievan, Branko, Connors, Jeremy, He, Jiasen, Khazal, Sajad, Yedururi, Sireesha, Dai, Julia, Garces, Sofia, Quesada, Andres E., Roth, Michael, Garcia, Miriam, McCall, David, Gibson, Amber, Ragoonanan, Dristhi, Petropoulos, Demetrios, Tewari, Priti, Nunez, Cesar, Mahadeo, Kris M., Tasian, Sarah K., Lamble, Adam J., Pawlowska, Anna, Hammond, Danielle, Maiti, Abhishek, Haddad, Fadi G., Senapati, Jayatsu, Daver, Naval, Gangat, Naseema, Konopleva, Marina, Meshinchi, Soheil, and Pemmaraju, Naveen

Published
2023
Full Text
View/download PDF

17. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Author

Aakash, Fnu, Gisriel, Savanah D., Zeidan, Amer M., Bennett, John M., Bejar, Rafael, Bewersdorf, Jan Philipp, Borate, Uma M., Boultwood, Jacqueline, Brunner, Andrew M., Buckstein, Rena, Carraway, Hetty E., Churpek, Jane E., Daver, Naval G., DeZern, Amy E., Efficace, Fabio, Fenaux, Pierre, Figueroa, Maria E., Garcia-Manero, Guillermo, Gore, Steven D., Greenberg, Peter L., Griffiths, Elizabeth A., Halene, Stephanie, Hourigan, Christopher S., Kim, Tae Kon, Kim, Nina, Komrokji, Rami S., Kutchroo, Vijay K., List, Alan F., Little, Richard F., Majeti, Ravindra, Nazha, Aziz, Nimer, Stephen D., Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M., Platzbecker, Uwe, Della Porta, Matteo G., Roboz, Gail J., Sallman, David A., Santini, Valeria, Sanz, Guillermo, Savona, Michael R., Sekeres, Mikkael A., Stahl, Maximilian, Starczynowski, Daniel T., Steensma, David P., Taylor, Justin, Abdel-Wahab, Omar, Wei, Andrew H., Xie, Zhuoer, Xu, Mina L., Hasserjian, Robert P., and Loghavi, Sanam

Published
2024
Full Text
View/download PDF

20. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial

Author

Konopleva, Marina Y., Dail, Monique, Daver, Naval G., Garcia, Jacqueline S., Jonas, Brian A., Yee, Karen W.L., Kelly, Kevin R., Vey, Norbert, Assouline, Sarit, Roboz, Gail J., Paolini, Stefania, Pollyea, Daniel A., Tafuri, Agostino, Brandwein, Joseph M., Pigneux, Arnaud, Powell, Bayard L., Fenaux, Pierre, Olin, Rebecca L., Visani, Giuseppe, Martinelli, Giovanni, Onishi, Maika, Wang, Jue, Huang, Weize, Dunshee, Diana R., Hamidi, Habib, Ott, Marion G., Hong, Wan-Jen, and Andreeff, Michael

Published
2024
Full Text
View/download PDF

21. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Author

Hammond, Danielle, Loghavi, Sanam, Wang, Sa A., Konopleva, Marina Y., Kadia, Tapan M., Daver, Naval G., Ohanian, Maro, Issa, Ghayas C., Alvarado, Yesid, Short, Nicholas J., Sasaki, Koji, Pemmaraju, Naveen, Montalban-Bravo, Guillermo, Lachowiez, Curtis A., Maiti, Abhishek, Garcia-Manero, Guillermo, Jabbour, Elias J., Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Pierce, Sherry R., Kantarjian, Hagop M., and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

23. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

Author

Senapati, Jayastu, Muftuoglu, Muharrem, Ishizawa, Jo, Abbas, Hussein A., Loghavi, Sanam, Borthakur, Gautam, Yilmaz, Musa, Issa, Ghayas C., Dara, Samuel I., Basyal, Mahesh, Li, Li, Naqvi, Kiran, Pourebrahim, Rasoul, Jabbour, Elias J., Kornblau, Steven M., Short, Nicholas J., Pemmaraju, Naveen, Garcia-Manero, Guillermo, Ravandi, Farhad, Khoury, Joseph, Daver, Naval, Kantarjian, Hagop M., Andreeff, Michael, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

26. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Author

Fiskus, Warren, Piel, Jessica, Collins, Mike, Hentemann, Murphy, Cuglievan, Branko, Mill, Christopher P., Birdwell, Christine E., Das, Kaberi, Davis, John A., Hou, Hanxi, Jain, Antrix, Malovannaya, Anna, Kadia, Tapan M., Daver, Naval, Sasaki, Koji, Takahashi, Koichi, Hammond, Danielle, Reville, Patrick K., Wang, Jian, Loghavi, Sanam, Sen, Rwik, Ruan, Xinjia, Su, Xiaoping, Flores, Lauren B., DiNardo, Courtney D., and Bhalla, Kapil N.

Published
2024
Full Text
View/download PDF

28. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

Author

Bazinet, Alexandre, Garcia-Manero, Guillermo, Short, Nicholas, Alvarado, Yesid, Bataller, Alex, Abuasab, Tareq, Islam, Rabiul, Montalbano, Kathryn, Issa, Ghayas, Maiti, Abhishek, Yilmaz, Musa, Jain, Nitin, Masarova, Lucia, Kornblau, Steven, Jabbour, Elias, Montalban-Bravo, Guillermo, Rausch, Caitlin R, Pierce, Sherry, DiNardo, Courtney D, Kadia, Tapan, Daver, Naval, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2024
Full Text
View/download PDF

30. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

Author

Daver, Naval G, Montesinos, Pau, DeAngelo, Daniel J, Wang, Eunice S, Papadantonakis, Nikolaos, Todisco, Elisabetta, Sweet, Kendra L, Pemmaraju, Naveen, Lane, Andrew A, Torres-Miñana, Laura, Thompson, James E, Konopleva, Marina Y, Sloss, Callum M, Watkins, Krystal, Bedse, Gaurav, Du, Yining, Malcolm, Kara E, Zweidler-McKay, Patrick A, and Kantarjian, Hagop M

Published
2024
Full Text
View/download PDF

31. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study

Author

Bataller, Alex, Montalban-Bravo, Guillermo, Bazinet, Alexandre, Alvarado, Yesid, Chien, Kelly, Venugopal, Sangeetha, Ishizawa, Jo, Hammond, Danielle, Swaminathan, Mahesh, Sasaki, Koji, Issa, Ghayas C, Short, Nicholas J, Masarova, Lucia, Daver, Naval G, Kadia, Tapan M, Colla, Simona, Qiao, Wei, Huang, Xuelin, Kanagal-Shamanna, Rashmi, Hendrickson, Stephany, Ravandi, Farhad, Jabbour, Elias, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

32. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Author

Bataller, Alex, Bazinet, Alexandre, DiNardo, Courtney D., Maiti, Abhishek, Borthakur, Gautam, Daver, Naval G., Short, Nicholas J., Jabbour, Elias J., Issa, Ghayas C., Pemmaraju, Naveen, Yilmaz, Musa, Montalban-Bravo, Guillermo, Takahashi, Koichi, Loghavi, Sanam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., and Kadia, Tapan M.

Published
2024
Full Text
View/download PDF

34. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Author

Senapati, Jayastu, Urrutia, Samuel, Loghavi, Sanam, Short, Nicholas J., Issa, Ghayas C., Maiti, Abhishek, Abbas, Hussein A., Daver, Naval G., Pemmaraju, Naveen, Pierce, Sherry, Chien, Kelly S., Sasaki, Koji, Kadia, Tapan M., Hammond, Danielle E., Borthakur, Gautam, Patel, Keyur, Ravandi, Farhad, Kantarjian, Hagop M., Garcia-Manero, Guillermo, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

35. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Author

Stahl, Maximilian, Bewersdorf, Jan Philipp, Xie, Zhuoer, Porta, Matteo Giovanni Della, Komrokji, Rami, Xu, Mina L., Abdel-Wahab, Omar, Taylor, Justin, Steensma, David P., Starczynowski, Daniel T., Sekeres, Mikkael A., Sanz, Guillermo, Sallman, David A., Roboz, Gail J., Platzbecker, Uwe, Patnaik, Mrinal M., Padron, Eric, Odenike, Olatoyosi, Nimer, Stephen D., Nazha, Aziz, Majeti, Ravi, Loghavi, Sanam, Little, Richard F., List, Alan F., Kim, Tae Kon, Hourigan, Christopher S., Hasserjian, Robert P., Halene, Stephanie, Griffiths, Elizabeth A., Gore, Steven D., Greenberg, Peter, Figueroa, Maria E., Fenaux, Pierre, Efficace, Fabio, DeZern, Amy E., Daver, Naval G., Churpek, Jane E., Carraway, Hetty E., Buckstein, Rena, Brunner, Andrew M., Boultwood, Jacqueline, Borate, Uma, Bejar, Rafael, Bennett, John M., Wei, Andrew H., Santini, Valeria, Savona, Michael R., and Zeidan, Amer M.

Published
2023
Full Text
View/download PDF

36. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results

Author

Sasaki, Koji, Morita, Kiyomi, Kantarjian, Hagop, Garcia-Manero, Guillermo, Jabbour, Elias, Ravandi, Farhad, Konopleva, Marina, Borthakur, Gautam, Wierda, William, Daver, Naval, Takahashi, Koichi, DiNardo, Courtney, Bravo, Guillermo Montalban, Issa, Ghayas C., Pierce, Sherry A., Soltysiak, Kelly A., Tingen, Martha S., and Cortes, Jorge E.

Published
2023
Full Text
View/download PDF

37. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

Author

Shallis, Rory M, Daver, Naval, Altman, Jessica K, Komrokji, Rami S, Pollyea, Daniel A, Badar, Talha, Bewersdorf, Jan P, Bhatt, Vijaya R, de Botton, Stéphane, de la Fuente Burguera, Adolfo, Carraway, Hetty E, Desai, Pinkal, Dillon, Richard, Duployez, Nicolas, El Chaer, Firas, Fathi, Amir T, Freeman, Sylvie D, Gojo, Ivana, Grunwald, Michael R, Jonas, Brian A, Konopleva, Marina, Lin, Tara L, Mannis, Gabriel N, Mascarenhas, John, Michaelis, Laura C, Mims, Alice S, Montesinos, Pau, Pozdnyakova, Olga, Pratz, Keith W, Schuh, Andre C, Sekeres, Mikkael A, Smith, Catherine C, Stahl, Maximilian, Subklewe, Marion, Uy, Geoffrey L, Voso, Maria Teresa, Walter, Roland B, Wang, Eunice S, Zeidner, Joshua F, Žučenka, Andrius, and Zeidan, Amer M

Published
2023
Full Text
View/download PDF

38. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Author

Yap, Timothy A., Daver, Naval, Mahendra, Mikhila, Zhang, Jixiang, Kamiya-Matsuoka, Carlos, Meric-Bernstam, Funda, Kantarjian, Hagop M., Ravandi, Farhad, Collins, Meghan E., Francesco, Maria Emilia Di, Dumbrava, Ecaterina E., Fu, Siqing, Gao, Sisi, Gay, Jason P., Gera, Sonal, Han, Jing, Hong, David S., Jabbour, Elias J., Ju, Zhenlin, Karp, Daniel D., Lodi, Alessia, Molina, Jennifer R., Baran, Natalia, Naing, Aung, Ohanian, Maro, Pant, Shubham, Pemmaraju, Naveen, Bose, Prithviraj, Piha-Paul, Sarina A., Rodon, Jordi, Salguero, Carolina, Sasaki, Koji, Singh, Anand K., Subbiah, Vivek, Tsimberidou, Apostolia M., Xu, Quanyun A., Yilmaz, Musa, Zhang, Qi, Li, Yuan, Bristow, Christopher A., Bhattacharjee, Meenakshi B., Tiziani, Stefano, Heffernan, Timothy P., Vellano, Christopher P., Jones, Philip, Heijnen, Cobi J., Kavelaars, Annemieke, Marszalek, Joseph R., and Konopleva, Marina

Published
2023
Full Text
View/download PDF

39. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Author

Zeidan, Amer M., Bewersdorf, Jan Philipp, Buckstein, Rena, Sekeres, Mikkael A., Steensma, David P., Platzbecker, Uwe, Loghavi, Sanam, Boultwood, Jacqueline, Bejar, Rafael, Bennett, John M., Borate, Uma, Brunner, Andrew M., Carraway, Hetty, Churpek, Jane E., Daver, Naval G., Della Porta, Matteo, DeZern, Amy E., Efficace, Fabio, Fenaux, Pierre, Figueroa, Maria E., Greenberg, Peter, Griffiths, Elizabeth A., Halene, Stephanie, Hasserjian, Robert P., Hourigan, Christopher S., Kim, Nina, Kim, Tae Kon, Komrokji, Rami S., Kutchroo, Vijay, List, Alan F., Little, Richard F., Majeti, Ravi, Nazha, Aziz, Nimer, Stephen D., Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M., Roboz, Gail J., Sallman, David A., Sanz, Guillermo, Stahl, Maximilian, Starczynowski, Daniel T., Taylor, Justin, Xie, Zhuoer, Xu, Mina, Savona, Michael R., Wei, Andrew H., Abdel-Wahab, Omar, and Santini, Valeria

Published
2022
Full Text
View/download PDF

40. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Author

Short, Nicholas J., Ong, Faustine, Ravandi, Farhad, Nogueras-Gonzalez, Graciela, Kadia, Tapan M., Daver, Naval, DiNardo, Courtney D., Konopleva, Marina, Borthakur, Gautam, Oran, Betul, Al-Atrash, Gheath, Mehta, Rohtesh, Jabbour, Elias J., Yilmaz, Musa, Issa, Ghayas C, Maiti, Abhishek, Champlin, Richard E, Kantarjian, Hagop, Shpall, Elizabeth J, and Popat, Uday

Published
2023
Full Text
View/download PDF

41. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Author

Bewersdorf, Jan Philipp, Xie, Zhuoer, Bejar, Rafael, Borate, Uma, Boultwood, Jacqueline, Brunner, Andrew M., Buckstein, Rena, Carraway, Hetty E., Churpek, Jane E., Daver, Naval G., Porta, Matteo Giovanni Della, DeZern, Amy E., Fenaux, Pierre, Figueroa, Maria E., Gore, Steven D., Griffiths, Elizabeth A., Halene, Stephanie, Hasserjian, Robert P., Hourigan, Christopher S., Kim, Tae Kon, Komrokji, Rami, Kuchroo, Vijay K., List, Alan F., Loghavi, Sanam, Majeti, Ravindra, Odenike, Olatoyosi, Patnaik, Mrinal M., Platzbecker, Uwe, Roboz, Gail J., Sallman, David A., Santini, Valeria, Sanz, Guillermo, Sekeres, Mikkael A., Stahl, Maximilian, Starczynowski, Daniel T., Steensma, David P., Taylor, Justin, Abdel-Wahab, Omar, Xu, Mina L., Savona, Michael R., Wei, Andrew H., and Zeidan, Amer M.

Published
2023
Full Text
View/download PDF

42. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

Author

DiNardo, Courtney D., Venugopal, Sangeetha, Lachowiez, Curtis, Takahashi, Koichi, Loghavi, Sanam, Montalban-Bravo, Guillermo, Wang, Xuemei, Carraway, Hetty, Sekeres, Mikkael, Sukkur, Ameenah, Hammond, Danielle, Chien, Kelly, Maiti, Abhishek, Masarova, Lucia, Sasaki, Koji, Alvarado, Yesid, Kadia, Tapan, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Kantarjian, Hagop M., Patel, Bhumika, Dezern, Amy, Roboz, Gail, and Garcia-Manero, Guillermo

Published
2023
Full Text
View/download PDF

43. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Senapati, Jayastu, Jain, Nitin, Huang, Xuelin, Daver, Naval, DiNardo, Courtney D, Pemmaraju, Naveen, Wierda, William, Garcia-Manero, Guillermo, Montalban Bravo, Guillermo, Sasaki, Koji, Kadia, Tapan M, Khoury, Joseph, Wang, Sa A, Haddad, Fadi G, Jacob, Jovitta, Garris, Rebecca, Ravandi, Farhad, and Kantarjian, Hagop M

Published
2023
Full Text
View/download PDF

44. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Author

Jain, Nitin, Senapati, Jayastu, Thakral, Beenu, Ferrajoli, Alessandra, Thompson, Philip, Burger, Jan, Basu, Sreyashi, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Konopleva, Marina, Pemmaraju, Naveen, Parry, Erin, Wu, Catherine J., Khoury, Joseph, Bueso-Ramos, Carlos, Garg, Naveen, Wang, Xuemei, Lopez, Wanda, Ayala, Ana, O’Brien, Susan, Kantarjian, Hagop, Keating, Michael, Allison, James, Sharma, Padmanee, and Wierda, William

Published
2023
Full Text
View/download PDF

45. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Author

Issa, Ghayas C., Bidikian, Aram, Venugopal, Sangeetha, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan M., Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Yilmaz, Musa, Short, Nicholas J., Maiti, Abhishek, Sasaki, Koji, Masarova, Lucia, Pierce, Sherry, Takahashi, Koichi, Tang, Guilin, Loghavi, Sanam, Patel, Keyur, Andreeff, Michael, Bhalla, Kapil, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop, and Daver, Naval

Published
2023
Full Text
View/download PDF

46. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Author

Daver, Naval G., Dail, Monique, Garcia, Jacqueline S., Jonas, Brian A., Yee, Karen W. L., Kelly, Kevin R., Vey, Norbert, Assouline, Sarit, Roboz, Gail J., Paolini, Stefania, Pollyea, Daniel A., Tafuri, Agostino, Brandwein, Joseph M., Pigneux, Arnaud, Powell, Bayard L., Fenaux, Pierre, Olin, Rebecca L., Visani, Giuseppe, Martinelli, Giovanni, Onishi, Maika, Wang, Jue, Huang, Weize, Green, Cherie, Ott, Marion G., Hong, Wan-Jen, Konopleva, Marina Y., and Andreeff, Michael

Published
2023
Full Text
View/download PDF

48. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity

Author

Bazinet, Alexandre, Kadia, Tapan, Short, Nicholas J., Borthakur, Gautam, Wang, Sa A., Wang, Wei, Loghavi, Sanam, Jorgensen, Jeffrey, Patel, Keyur, DiNardo, Courtney, Daver, Naval, Alvarado, Yesid, Haddad, Fadi G., Pierce, Sherry, Gonzalez, Graciela Nogueras, Maiti, Abhishek, Sasaki, Koji, Yilmaz, Musa, Thompson, Philip, Wierda, William, Garcia-Manero, Guillermo, Andreeff, Michael, Jabbour, Elias, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2023
Full Text
View/download PDF

49. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Jain, Nitin, Huang, Xuelin, Montalban-Bravo, Guillermo, Banerjee, Pinaki, Rezvani, Katayoun, Jiang, Xianli, Kim, Kun Hee, Kanagal-Shamanna, Rashmi, Khoury, Joseph D, Patel, Keyur, Kadia, Tapan M, Daver, Naval, Chien, Kelly, Alvarado, Yesid, Garcia-Manero, Guillermo, Issa, Ghayas C, Haddad, Fadi G, Kwari, Monica, Thankachan, Jennifer, Delumpa, Ricardo, Macaron, Walid, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop

Published
2023
Full Text
View/download PDF

50. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.

Author

Kugler, Eitan, primary, Dasdemir, Enes, additional, Wang, Bofei, additional, Bataller, Alex, additional, Dinardo, Courtney Denton, additional, Daver, Naval Guastad, additional, Yilmaz, Musa, additional, Short, Nicholas James, additional, Kadia, Tapan M., additional, Sasaki, Koji, additional, Bazinet, Alexandre, additional, Pierce, Sherry, additional, Reville, Patrick Kevin, additional, Ravandi-Kashani, Farhad, additional, and Abbas, Hussein, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results